Castle Biosciences Inc
$ 24.37
3.57%
14 Apr - close price
- Market Cap 712,864,000 USD
- Current Price $ 24.37
- High / Low $ 24.81 / 23.72
- Stock P/E N/A
- Book Value 15.86
- EPS -0.83
- Next Earning Report 2026-05-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE -0.05 %
- 52 Week High 44.28
- 52 Week Low 14.59
About
Castle Biosciences Inc. is a pioneering company in the diagnostics sector, focused on transforming patient care through its innovative gene-expression profiling tests, particularly in skin cancer. Its leading product, DecisionDx®-Melanoma, plays a crucial role in the management of melanoma by providing vital insights into risk stratification and guiding treatment decisions based on gene expression analysis. Committed to advancing precision medicine, the company leverages its proprietary technology to develop additional assays that address significant clinical needs. With a strong emphasis on research and development and a promising pipeline, Castle Biosciences is well-positioned for sustainable growth while enhancing clinical outcomes and delivering value to shareholders in the dynamic oncology market.
Analyst Target Price
$48.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-11-03 | 2025-08-04 | 2025-04-30 | 2025-02-26 | 2024-11-04 | 2024-08-05 | 2024-05-02 | 2024-02-28 | 2023-11-02 | 2023-08-02 | 2023-05-03 |
| Reported EPS | -0.08 | -0.02 | 0.15 | -0.9035 | 0.32 | 0.08 | 0.31 | -0.09 | -0.1 | -0.26 | -0.7 | -1.1 |
| Estimated EPS | -0.32 | -0.52 | -0.51 | -0.0657 | 0.04 | -0.06 | -0.27 | -0.33 | -0.54 | -0.76 | -0.91 | -0.89 |
| Surprise | 0.24 | 0.5 | 0.66 | -0.8378 | 0.28 | 0.14 | 0.58 | 0.24 | 0.44 | 0.5 | 0.21 | -0.21 |
| Surprise Percentage | 75% | 96.1538% | 129.4118% | -1275.1903% | 700% | 233.3333% | 214.8148% | 72.7273% | 81.4815% | 65.7895% | 23.0769% | -23.5955% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-04 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.56 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CSTL
2026-04-10 20:10:14
Castle Biosciences (NASDAQ:CSTL) saw its share price drop by 7% on Friday, trading at $21.79 on significantly lower than average volume. Despite this decline, Wall Street analysts maintain a "Moderate Buy" consensus with an average price target of $47.57, driven by recent upgrades. The company's fundamentals show mixed signals, with beats on quarterly EPS and revenue estimates but negative net margin and P/E, alongside significant insider selling over the past 90 days.
2026-04-10 14:38:55
Castle Biosciences, Inc. (Nasdaq: CSTL) has been awarded the 2026 USA TODAY Top Workplaces USA Award for the fifth consecutive year. This recognition is based on confidential employee feedback and highlights the company's commitment to building a people-first workplace culture. CEO Derek Maetzold emphasized that valuing, supporting, and empowering team members is a continuous investment for the company.
2026-04-10 11:10:14
Castle Biosciences (Nasdaq: CSTL) has been awarded the 2026 USA TODAY Top Workplaces USA Award for the fifth consecutive year. This national award, based on confidential employee feedback, recognizes organizations with exceptional, people-first workplace cultures. The company's president and CEO, Derek Maetzold, highlighted the award as a direct reflection of the team's dedication and commitment to improving patient care.
2026-04-10 11:09:26
Castle Biosciences, a diagnostics company focused on improving health through innovative tests, has received the 2026 USA TODAY Top Workplaces USA Award for the fifth consecutive year. This recognition, awarded by Energage and USA TODAY, celebrates organizations with exceptional, people-first workplace cultures, as determined by confidential employee feedback. Derek Maetzold, president and CEO of Castle Biosciences, highlighted the award as a reflection of the team's dedication and the company's commitment to investing in a supportive and empowering work environment.
2026-04-10 07:00:00
Castle Biosciences, Inc. has received the 2026 USA TODAY Top Workplaces USA Award for the fifth consecutive year. This national recognition is based entirely on confidential employee feedback and highlights the company's commitment to building and nurturing a people-first workplace culture. The award, administered by Energage, celebrates organizations with exceptional employee engagement and a strong organizational commitment to their workforce.
2026-04-09 12:40:28
This Simply Wall St report provides a detailed analysis of Castle Biosciences (CSTL), a molecular diagnostics company focusing on dermatologic cancers and other conditions. It highlights the stock's valuation, future growth potential, past performance, and financial health, noting it is currently undervalued by analysts. The article also includes recent news, price performance, and key financial figures.
